ACTRIMS Forum

There are more than a dozen treatment options for patients with relapsing multiple sclerosis and so far none for the progressive form. Why that is and what can be done to change that are two of the biggest challenges in the field today.

Some of the finest minds in the field of multiple sclerosis were in New Orleans for the annual ACTRIMS conference all looking to share their knowledge and learn more before returning home to their patients.

Trips to the emergency department (ED) can range from the most benign to the most serious of reasons.

As researchers focus on finding treatments for progressive multiple sclerosis there are a number of potential angles to study to find the best treatment options possible. One potential area is the role of B cells in the treatment process.

Recently, researchers had discovered that HIV infection might decrease the risk of developing multiple sclerosis (MS).

New research has discovered high doses of biotin vastly improve neurologic function in a small percentage of patients afflicted with progressive MS.

Gut microbiota has been a trending area of study across all medical specialties, and poses a curious question in multiple sclerosis (MS) research.

While newer medications are constantly being developed for multiple sclerosis one of the original options may still be the best for some patients.

As the first medication designed to treat primary progressive multiple sclerosis moves closer to the market there are still many questions about how effective it will be and what other treatment options may look like in the future.

Prior research has shown women suffering from multiple sclerosis (MS) often have a more benign initial course than male patients. However, these same female patients tend to quickly transition to secondary progressive disease as their approach menopause.

In research presented at the ACTRIMS Forum in New Orleans, researchers raised an intriguing question: why has the median time of onset to diagnosis of MS increased for veterans of the Gulf War?

Canadian researchers found that a small percentage of MS patients tested positive for Lyme disease.

Magnetic Resonance Imaging (MRI) has long been the immediate go-to for “proof-of-concept†outcome measures in relapse-remitting multiple sclerosis (RRMS). After all, why fix what isn’t broken?

MRI scans were surprisingly lacking in sensitivity when it came to tracking the progress of MS. National Institutes of Health researchers came up with a new scale of measurement.

Obesity, along with the composition of the microbiome in the gut, have been suggested as being elements that may contribute to the risk of multiple sclerosis. Patients surveyed said they would be willing to change diet to see if it helped their illness.

For many years there were no approved treatments for patients with primary progressive multiple sclerosis. Recently, a concerted effort has been made to change that and get this patient population the help they so badly need.

Results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulators for relapsing multiple sclerosis (MS) patients showed significant reductions in the cumulative number of total gadolinium-enhancing (GdE) lesions.

In vivo detection, monitoring chronic inflammation, and repair/remyelination are all important in identifying biological targets and developments of new treatments in multiple sclerosis (MS).

Study results show that patients with multiple sclerosis may benefit from taking vitamin D3.

The US Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (Ocrevust/Roche).

Managing the cognitive impairment in patients suffering from multiple sclerosis (MS), has long been an integral focus of MS research.